Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 3000+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | August 27, 2026

Aug 27, 2026

•

3 min read

Biotech & Pharma Updates | August 27, 2026

🧬 Revolution Medicines' Rasonque (daraxonrasib) wins FDA approval for second-line pancreatic ductal adenocarcinoma, targeting RAS, AstraZeneca, Amgen's Tezspire (tezepelumab) hits Ph3 endpoints in eosinophilic esophagitis, targeting TSLP pathway, Artis BioSolutions opens Spanish facility, expanding synthetic DNA and mRNA production capabilities for genetic medicines

Christian Cuchapin, +1

Biotech & Pharma Updates | August 26, 2026

Aug 26, 2026

•

3 min read

Biotech & Pharma Updates | August 26, 2026

🧬 FDA approves Jazz Pharmaceuticals' Ziihera (zanidatamab) as first-line HER2-targeted therapy for gastroesophageal adenocarcinoma based on Ph3 data, Biohaven, SK Biopharmaceuticals partner on Kv7 epilepsy platform licensing deal worth up to $795M, FDA considers adding two deputy commissioner roles focused on AI/health and drugs

Christian Cuchapin, +1

Biotech & Pharma Updates | August 25, 2026

Aug 25, 2026

•

3 min read

Biotech & Pharma Updates | August 25, 2026

🧬 FDA grants Capricor Therapeutics three-month extension to review (deramiocel) Ph3 data for Duchenne muscular dystrophy upper limb indication, Johnson & Johnson's Imaavy (nipocalimab) gains FDA label expansion for warm autoimmune hemolytic anemia backed by Ph2/3 data, Eli Lilly launches oral obesity pill Foundayo in UK, challenging Novo Nordisk's head-start Wegovy pill

Christian Cuchapin, +1

Biotech & Pharma Updates | August 24, 2026

Aug 24, 2026

•

3 min read

Biotech & Pharma Updates | August 24, 2026

🧬 Roche, Hanmi Pharm partner on weight loss drug HM17321, $190M upfront, up to $2.3B deal, Lundbeck reports 16% sales growth in H1 2026, driven by Vyepti and Rexulti gains, Spruce Biosciences advances toward Q4 FDA filing for ultra-rare Sanfilippo syndrome drug after successful manufacturing talks

Christian Cuchapin, +1

Biotech & Pharma Updates | August 21, 2026

Aug 21, 2026

•

2 min read

Biotech & Pharma Updates | August 21, 2026

🧬Roche invests $750M to double Oregon Genentech facility, adding fill-finish manufacturing capacity by 2031, Werewolf Therapeutics, Ambros Therapeutics merge in $150M deal targeting rare CRPS-1 pain disorder, Aurinia Pharmaceuticals settles with Teva Pharmaceuticals, protecting Lupkynis from generics until December 2036

Christian Cuchapin, +1

Biotech & Pharma Updates | August 20, 2026

Aug 20, 2026

•

3 min read

Biotech & Pharma Updates | August 20, 2026

🧬 Ultragenyx wins first gene therapy FDA approval for Genglycos (DTX401) targeting glycogen storage disease type Ia via Ph3, Kynexis raises €97M ($113M) Series A, advancing cognitive impairment schizophrenia drug to registrational development, Regeneron wins FDA approval for Pasatru (garetosmab) targeting Activin A in fibrodysplasia ossificans progressiva based on Ph3 data

Christian Cuchapin, +1

Aug 19, 2026

•

3 min read

Biotech & Pharma Updates | August 19

🧬 Merck & Co., Moderna's intismeran autogene (mRNA-4157) plus Keytruda (pembrolizumab) reduces recurrence risk in Ph3 melanoma trial, Trump nominates White House aide Heidi Overton as new FDA commissioner, CSL shares surge 17% on immunoglobulin demand recovery and stronger-than-expected $15.8B revenue

Christian Cuchapin, +1

Biotech & Pharma Updates | August 18, 2026

Aug 18, 2026

•

3 min read

Biotech & Pharma Updates | August 18, 2026

🧬 Amylyx Pharmaceuticals eyes FDA filing for (avexitide) after Ph3 win in post-bariatric hypoglycemia, BioMarin Pharmaceutical acquires Alesta Therapeutics for $275M to challenge AstraZeneca in rare bone disease market, Biokin Pharma's (iza-bren) EGFRxHER3 bispecific ADC meets Ph3 primary endpoint in EGFR-mutated nonsquamous non-small cell lung cancer

Christian Cuchapin, +1

Biotech & Pharma Updates | August 17, 2026

Aug 17, 2026

•

3 min read

Biotech & Pharma Updates | August 17, 2026

🧬 Vera Therapeutics' Trutakna shows kidney function stabilization in Ph3, rivaling Otsuka's Voyxact in immunoglobulin A nephropathy, Slate Medicines reverse merges with Fulcrum Therapeutics, raises $245M for migraine antibody trials on Nasdaq, AstraZeneca's Tagrisso (osimertinib) plus Orpathys (savolitinib) meets PFS and overall survival goals in Ph3 EGFR-mutated non-small-cell lung cancer trial

Christian Cuchapin, +1

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | August 27, 2026

Biotech & Pharma Updates | August 26, 2026

Biotech & Pharma Updates | August 25, 2026

Biotech & Pharma Updates | August 24, 2026

Biotech & Pharma Updates | August 21, 2026

Biotech & Pharma Updates | August 20, 2026

Biotech & Pharma Updates | August 19

Biotech & Pharma Updates | August 18, 2026

Biotech & Pharma Updates | August 17, 2026

TLDR Biotech

FAQ

Media Partners